Skip to main content
Premium Trial:

Request an Annual Quote

DiaCarta Raises $45M in Series B Funding

NEW YORK (GenomeWeb) – DiaCarta said today that it has completed a Series B funding round, raising a total of $45 million. The second closing was led by Fortune Fountain Capital and included an investment from Good Health Capital.

DiaCarta Founder and CEO Aiguo Zhang said in a statement that the financing will support continued development of the company’s core XNA technology platform, and will support work to expand its diagnostic products for non-invasive early detection and monitoring of cancers. This will include establishing global clinical study programs in various areas, the commercial launch of the firm's liquid biopsy ColoScape assay for the detection of colorectal cancer, and the inception of new product development pipelines.

Funds raised will also help support future marketing applications to the US and China Food and Drug Administrations for relevant tests, Zhang said.

 

The Scan

Cell Atlas of Human Lung Development Gives View of Developing Airway

Researchers have generated a cell atlas of human lung development, which they report in Cell.

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.